Australia markets closed
  • ALL ORDS

    7,239.40
    +30.40 (+0.42%)
     
  • ASX 200

    7,014.20
    +31.50 (+0.45%)
     
  • AUD/USD

    0.7783
    +0.0052 (+0.68%)
     
  • OIL

    65.41
    +1.59 (+2.49%)
     
  • GOLD

    1,843.10
    +19.10 (+1.05%)
     
  • BTC-AUD

    64,627.52
    +1,035.82 (+1.63%)
     
  • CMC Crypto 200

    1,407.40
    +48.84 (+3.60%)
     
  • AUD/EUR

    0.6406
    +0.0013 (+0.20%)
     
  • AUD/NZD

    1.0735
    -0.0017 (-0.16%)
     
  • NZX 50

    12,367.86
    -60.26 (-0.48%)
     
  • NASDAQ

    13,395.87
    +286.72 (+2.19%)
     
  • FTSE

    7,043.61
    +80.28 (+1.15%)
     
  • Dow Jones

    34,391.98
    +370.53 (+1.09%)
     
  • DAX

    15,416.64
    +216.96 (+1.43%)
     
  • Hang Seng

    28,027.57
    +308.90 (+1.11%)
     
  • NIKKEI 225

    28,084.47
    +636.46 (+2.32%)
     

Class Action Update - NFLX, KPTI & MNK - Bronstein, Gewirtz & Grossman, LLC

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Sept. 13, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Netflix, Inc. (NASDAQ: NFLX)
Class Period: April 17, 2019 - July 17, 2019
Deadline: September 20, 2019
For more info: www.bgandg.com/nflx
The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Netflix would not be able to gain its expected target number of new subscribers in the second quarter of 2019; (2) Netflix would also lose subscribers from the United States in the second quarter of 2019; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.

Karyopharm Therapeutics Inc. (KPTI)
Class Period: March 2, 2017 - February 22, 2019
Deadline: September 23, 2019
For more info:
www.bgandg.com/kpti
The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that material adverse information. The complaint continues to allege that Karyopharm hyped the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured shareholders that it was “well tolerated” by patients. The complaint also states that Karyopharm declared that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.

Mallinckrodt plc (MNK)
Class Period: February 28, 2018 - July 16, 2019
Deadline: September 24, 2019
For more info: www.bgandg.com/mnk
The lawsuit alleges that throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (2) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (3) as a result, the Company’s public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com